Probiotic Effects on Covid-19

Rana H. Raheema *,†, Marwa A. Al-Asady *

*College of Medicine, Wasit University, Iraq

Abstract
This study focuses on the impacts of probiotics on covid-19 infection. Probiotics have the ability for enhancing gastrointestinal tract health, modulating the immune system and reducing the occurrence of allergy in susceptible people.

In addition, probiotics are capable of supporting the host's immune system to fight viral infections. There is a relationship between COVID-19 disease and intestinal dysbiosis, also there are close links between gastrointestinal tract and respiratory tract infection.

Probiotics can restore the composition of the gut microbiota “eubiosis”, also regulating the immune response in respiratory tract infection and acts as an anti-inflammatory that can reduce the inflammation/cytokine storm and other symptoms (vomiting, diarrhea) in COVID-19 infection.

Also, strains that are related to the lactic acid bacteria (probiotic) might change the human intestine/gut microbiota through opportunistic bacteria growth suppression. Thus, stimulation and administration of the activity and growth of probiotic strains in intestine/gut might be specified as possible method for controlling food borne enteric pathogens.

There were numerous health advantages to the probiotics elsewhere in the gut; the probiotics have exposed for improving the immunity, reducing severity regarding specific allergic conditions and deliberate a few anti carcinogenic characteristics.

Keywords: probiotics, COVID-19, Immunity, Lactobacillus spp.

1. Introduction
Probiotics are defined as live microorganisms which, in the case when being administered in passable amounts, provide many health benefits to the host (Hill et al., 2014).

Lactobacillus species, Saccharomyces and Bifidobacterium were the most prevalent microorganisms as probiotic (Guimaraes et al., 2020; Zendeboodi et al., 2020).

They were commercially available as added to certain dairy products and food, also supplements (Kiousi et al., 2019; de Almada et al., 2015; Roobab et al. 2020). There were prebiotics, which have been substrates consumed selectively via the host micro-organisms and conferring health benefits (NeriNuma et al., 2020). Also, strains that are related to the lactic acid bacteria (probiotic) might change the human intestine/gut microbiota through opportunistic bacteria growth suppression. Thus, stimulation and administration of the activity and growth of probiotic strains in intestine/gut might be specified as possible method for controlling food borne enteric pathogens.

* Corresponding author
E-mail addresses: rraheema@uowasit.edu.iq (R.H. Raheema)
There were numerous health advantages to the probiotics elsewhere in the gut; the probiotics have exposed for improving the immunity, reducing severity regarding specific allergic conditions and deliberate a few anti carcinogenic characteristics. There were limited data provided regarding the effects of COVID19 upon the intestinal microbiota (Khaneghah et al., 2020). SARS-CoV2 might proliferate in gastrointestinal and respiratory tracts (Lamers et al., 2020). It has been indicated that COVID19 is affecting the functioning and composition of digestive tract; thus, changing the gut microbiota for long periods (Mohanty, Dhar, 2020).

A few researches showed that the probiotics might have possible anti-viral and anti-inflammatory effects. They are acting via the suppressing production of cytokines whether locally, for instance, on levels of the intestinal mucosa, or on extra intestinal organs of the body. Many medical trials specified that the probiotics’ administration to enhance the effects in conditions that are associated with the immune system as well as viral infection (Kiouisi et al., 2019).

**SARS-COV-2 (COVID-19 infection)**

Coronaviruses are specified as members of the enveloped positive sense viruses of the RNA, belonging to Nidovirales order that is related to Coronaviridae family. Also, the distinctive properties of glycoprotein spikes on the surface of the virus are promoting its easy adhesion and identification with the cells of the host. Corona viral RNA has been large up to 32kb (Hulswit et al., 2016).

Also, the coronavirus that is associated with the animal and human hosts has been classified to 4 genera, delta, gamma, beta and alpha viruses. In addition, the alpha coronavirus involves human isolates Human Coronavirus 229E (HCoV-229E) and HCoVNL63, while beta coronavirus includes HCoV-OC43, HCoVHKUL and the recently-included SARS-CoV, MERS-CoV, and SARS-CoV-2 (COVID-19) (Zaki et al., 2012; Drosten et al., 2003; Zhu et al., 2020a). COVID-19, the latest CoV outbreaks that was started in Wuhan, China in 2019, is the results of SARS-CoV-2 (Gorbalenya et al., 2020; Zhou et al., 2020a). The virus was categorized in family Coronaviridae, order Nidovirales, Beta-coronavirus genus and subfamily Coronavirinae. On December 2020, over 50 million SARS-Cov-2 infections were identified all over the world.

To initiate the infection of SARS-CoV-2 adhering to the ACE2, receptor on epithelial cells that are related to hosts via their surface glycoprotein spikes, S1 and S2 (Hoffmann et al., 2020).

In addition, ACE2 has been expressed mostly in lung type-II pneumocytes, colon colonocytes, cholangiocytes, ileum endothelial cells, esophagus keratinocytes, stomach epithelial cells, kidney proximal tubules, and rectum endothelial cells (Qi et al., 2020). N-terminal S-1 portion regarding viral S protein is of high importance in the targeting of host cell receptor ACE-2. Receptor binding was facilitated through C-terminal receptor binding domain on S 1 portion (Wu et al., 2009; Li et al., 2005; Reguera et al., 2012; Li, 2012). Following the binding of the receptor through S 1 portion, S 2 portion facilitate fusion between viral as well as host cell membrane. Also, S 2 portion has many fusion peptides and 2 conserved repeats of the heptad that were vital in direction finding in addition to the fusion of virus via cell membrane (Lu et al., 2015). After SARS-CoV2 genome release to the host cell’s cytoplasm, viral RNA will be replicated and following (2-14) days of the incubation, the symptoms of infection will emerge, yet some targets are without symptoms, and scanning might be confirming infection alone (Fanos et al., 2020).

Throughout the start of sickness, the major symptoms shown via the majority of patients were cough and fever. Other symptoms such as fatigue or muscle pain (myalgia), conjunctivitis, shortness of breath (dyspnea), headache, diarrhea, chest pains, runny nose (rhinorrhea), nausea, vomiting, gastrointestinal bleeding, loss of appetite, abdominal pains, coughing of blood (hemoptysis) and autoimmune hemolytic anemia (D’Amico et al., 2020; Huang et al., 2020; Chen et al., 2020b; Wang et al., 2020b; Dockery et al., 2020; Kopel et al., 2020; Lazarian et al., 2020).

Also, patients have stated dysgeusia (distortion of taste sense) and anosmia (loss of smell) (Azez et al., 2020; Hopkins et al., 2020; Mermelstein, 2020; Nunan, 2020). With regard to asymptomatic patients of SARS-CoV2, anosmia, dysgeusia, or hyposmia were the symptoms which have been suggestive of the screening (Lao et al., 2020).

**Immune response in COVID-19**

Like all infections, the innate/adaptive immune system should be mounting effective defenses against a viral invasion. COVID-19 has been reported circulating T-helper cells (CD 4 +
cells), B-cells, Cytotoxic T-cells (CD 8+ cells), lymphocytes, natural killers’ cells (NKs), eosinophils, monocytes and basophils are declined (Kuri-Cervantes et al., 2020; Wu et al., 2020c; Xu et al., 2020b; Huang et al., 2020).

The immunity against SARS-CoV-2 antigen gets functional loss. Dysregulation that is related to macrophage and monocyte function is promoting a marked decrease in CD16+ monocytes as well as an insignificant increases in CD14+ monocytes (Wilk et al., 2020).

In addition, the up regulation of CD14+ monocytes could be because of the secretion of IL6 through inflammatory monocytes. (Zhou et al., 2020). The accumulations of the macrophages at infection site are stimulating the fibroblasts to result in pulmonary fibrosis (PFs). Also, peripheral NKs are losing their functional impacts in the severe SARS-CoV2 infections and have been decreased, while there was an increase in lymphopenia and apoptosis (Xiong et al., 2020).

DCs are capturing the viral antigen as well as presenting it to T-cells which exist in lymphoid tissues and mucus epithelium. Also, they are secreting cytokines for regulating immune responses (I.R) as well as maintaining the homeostatic equilibrium which is disturbed because of virus infection. Along with phagocytosis, the DCs are inducing adaptive immunity towards the viral antigens.

Plasmacytoid DCs (pDC) and myeloid DCs (mDCs) have activated anti-viral responses through creating a considerable amounts of type-I interferon (INF) and making immune surveillances in air route as well as distal lung via intrinsic, innate receptors, with the use of RIG-1, MDA5, RNA sensing TLRs7 & 8 and NLRP3 inflammasome (Gupta et al., 2020). Throughout presentation of antigen to T-cells, APC has been extremely specific. In the case where it is interacting with CD 4+ T-cells, it will be differentiated to Th cells of various types Th2, Th 1, Th17 or other CD4+ T-cells. Its secretions, like chemokines and cytokines are influencing such T-cell process. With regard to the differentiation of naive CD4+T-cells, DCs are secreting the cytokine, IL-16. According to the antigen, DCs are activating various cytokine genes. DCs' surface has receptors referred to as TLRs.

TLRs is identifying the pathogen’s nature as well as sending signals for turning on specific cytokine genes. Also, the cytokine IL12 is inducing the T-cells for differentiating the sub-set Th1 cells. Also, the cytokine IL23 allow differentiating the T-cells into Th17 cells which are contracting with the extra cellular antigens. Besides, IL-4 is converting the T-cells into Th 2 Cells which are promoting productions of the antibodies via B-cells. Activated DCs are secreting the TGF-beta as well as IL-10 which is promoting the T-regulatory cells that are inducing immune responses.

DCs are initiating the innate immune response via NK T-cells, NKs and gamma-sigma T-cells. In addition, the stimulating viral improves the population of pDC, and it is secreting the IFN-gamma as a response to the viral antigen challenges (Ahmad-Hasan et al., 2020). Besides, pDC cross key naive CD8+T-cells through the transfer of the antigen into traditional DCs via exosomes. COVID-19 is interfering with secretory activities that are related to immune cells. Due to the acute infections, up regulations of chemokines results in heavy entry of monocytes, neutrophils and macrophages to sites that have been infected, leading to cytokine storm and tissue damage. With regard to acute cases, the cytokine storm is promoting pro-inflammatory cytokines synthesis IL1 beta, IL2, and IL6 promoting disease complications (Fu et al., 2020). INF production causes an increase in the acute situations (McKechnie, Blish, 2020).

**Effects of probiotic in COVID-19**

Probiotics are decreasing the infection’s severity in upper respiratory tract and gastrointestinal tract through acting on adaptive and innate adaptive immune systems.

Now, using probiotic microorganisms as well as their metabolic products is representing a promising method to treat viral illnesses (Ryan et al., 2015). Also, the colonization related to intestinal epithelium via probiotic bacteria reduces the symptoms and rates of viral respiratory infections. This can be done via increasing the IgA expressing B-cells in the lymph nodes and colon along with an increase in the population of IL-23–expressing DCS and T-follicular helper cells (Kanauchi et al., 2018).

Gut and lung tissues are affected by COVID-19; therefore, inflammatory response is activated. It causes an increase in the proinflammatory cytokines IFN-gamma/TNF-alpha, which results in an increase in cytokine storm. The response might be because of the activation regarding Th1 cell responses in the tissues of the lungs (Letoranta et al., 2014). With regard to human gut environment, the dysbiosis in the microbiota of the gut leads to imbalances of Th1 and Th2, which is promoting the activation of pro inflammatory cytokine and lastly a cytokine storm in the lungs (Qian et al., 2017). After probiotics’ management, there has been a colonization of “good bacteria”
in the gut that results in shifting the balance between Th1/Th2 cells and decreasing the cytokine storm as well as the disease’s severity (Qian et al., 2017). Lately, it was identified that the medications with probiotic bacteria by means of \textit{Lactobacillus} and \textit{Bifidobacteria} are providing a considerable possibility of the recovery against \textit{Covid-19} (Fanos et al., 2020).

With regard to various conditions of severe \textit{Covid-19}, the occurrence of gastric symptoms has been reported. Due to the fact that the gastric symptoms are recorded, one might assume that \textit{Sars-CoV2} is interacting with the microbiota of the gut via gut/lung axis.

Today, it is indicated that it might be accountable for neuropsychiatric as well as cutaneous manifestations via the gut/skin, gut/brain and skin/brain axes (Salem et al., 2018; Charitos et al., 2020). \textit{Sars-CoV-2} results in local dysbiosis and, in try, the translocations that are related to microbial metabolites as well as toxins to other organs, like the gut. It must be indicated that the anti-virals and anti-biotics were majorly provided to patients experiencing \textit{Sars-CoV2}, that might result in the dysbiosis of the gut microbiota. Thus, intestinal dysbiosis and dysregulated inflammation has been triggered not just via the infection. Patient’s age or comorbidities might be behind the prime to higher disease severity and bad therapy results. Which could be an explanation for the increase in the \textit{Covid-19} severity because of the direct regulation regarding cross exchange between lung, intestine, skin and brain, which is increasing the immune dysregulation? (Angurana and Bansa, 2020; Gu et al., 2020; Riphagen et al., 2020).

Probiotic microbes are stimulating and modifying the immune system and reducing inflammations (Hardy et al., 2013). \textit{Bifidobacterium} species and \textit{Lactobacillus} species were the major traditional probiotics which might be utilized for balancing the expanded intestinal ecosystems in a fight of \textit{Sars-CoV2}. In addition, the basis for utilizing probiotics and treating \textit{Sars-CoV2} is coming from a few experimental researches and indirect suggestions. Also, probiotics, including \textit{Lactobacillus} can, achieve anti-viral actions, results in a eubiosis condition in the intestinal microbiota; therefore, contributing to the anti inflammatory effects and to super infection’s prevention. It is recommended to use probiotics, along with their metabolites surfactant fatty acids (SCFAs) for supporting adaptive and innate immunity in patients who have \textit{Sars-CoV2}, as adjuvant approach towards the complications. The basis for such line comes from various experimental indications (Ayawardena et al., 2020; Morais et al., 2020).

With regard to patients experiencing \textit{Covid-19}, probiotics might allow restoring the changed gut microbiota, also contributes to healthy gut-lung axis. Also, they might be reducing the pathogens translocation via intestinal mucosa and avoid overlying infections. Probiotics might be interfering with the entry of the virus to host cells and with their replications. \textit{Bifidobacterium} animals are inhibiting the replication of coronaviruses with anti-IL effects. \textit{Lactobacillus casei} ATCC39392 is stimulating the expression of IL-17 throughout coronavirus gastroenteritis (Morais et al., 2020; Walton et al., 2020).

\textit{Covid-19} prompted intestinal dysbiosis has been enhanced via nutritional supports with the \textit{Lactobacillus acidophilus} (Kagyama et al., 2020). Also, the \textit{Sars-CoV2} is damaging the epithelial layers of the gut. \textit{Lactobacillus plantarum} is reinforcing viral damaged mucus epithelial barrier as well as enhancing the transportation of the probiotics to the lungs by the lung/gut axis and affecting the adaptive and innate immunity in the gut related lymphoid tissue, secondary lymphoid organs (Lundstrom, 2020; Zhang et al., 2020).

\textit{Lactobacillus plantarum} shows anti-viral activity against the transmissible gastroenteritis virus, which is going to activate the anti-viral proteins through the signalling pathway of JAK-STAT, along with upregulating the interferon genes’ expressions, leading to anti transmissible gastro-enteritis virus activities (Wang et al., 2019). Those reports are further indicating the efficiency of probiotic strains for treating the coronavirus.

\textit{Lactobacillus reuteri} secretions such as reuterin, bacteriocins and reuteri-cyclin showing a rich anti-viral, anti-bacterial, anti-protozoan and anti-fungal activity. \textit{Lactobacillus reuteri} producing tryptophan derived indole derivatives AhR and downregulating Thpok production to result in re-programming of CD 4+ IELs into DPIEL which is enhancing the anti-microbial peptides production (Reg3-lectins) for stimulating the innate immune responses against the intestinal pathogens that induce inflammations (Ang et al., 2016; Chen et al., 2018).

\textit{Lactobacillus salivarius} in gut also improves the immunity towards the viruses inducing the inflammatory cytokines, IL10 (Zhai et al., 2020). \textit{Lactobacillus paracasei} prevent \textit{SARS-CoV-2}
binding with ACE-2 and its prevent entry the virus in the host cells and thereby resulted in the reduction of the infection chances (Rizo et al., 2020).

The ACE and di-peptidyl peptidase-4 that has been created by *Lactobacillus lactis* have immune-regulatory functions. Therefore, recombinant *Lactobacillus* vaccinations are planned towards the infection of COVID (Jiang et al., 2016). The *Lactobacillus casei* based oral vaccination towards transmissible gastro-enteritis corona virus stimulated Th-17 pathways. It resulted in the inhibition of the transmissible gastroenteritis corona virus. Numerous studies are performed all over the world, for the utilization of a variety of the *Lactobacillus* species as a new COVID-19 vaccination rector platform (Frederiksen et al., 2020; ISAPP, 2020).

Management of complex probiotic tablets *Lactobacillus paracasei, Lactobacillus acidophilus, Lactobacillus, Lactobacillus plantarum, delbrueckii, Bifidobacterium infantis, Bifidobacterium longum, Saccharomyces salivarius, and Bifidobacterium breve* to the children that have been admitted to ICU with the severe sepsis has been beneficial in increasing the anti-inflammatory cytokines (TGF-beta-1, IL10) and decreasing the levels of the pro-inflammatory cytokines (IL-6, TNF-alpha, IL12 and IL-17) (Angurana, Bansal, 2020; Guan et al., 2020). Administrating over 20 probiotics established at improving the levels of the anti-inflammatory ILs and antiviral antibodies productions, resulting in the reduction of viral loads (Wang et al., 2013; Ballini et al., 2019). Coronaviruses maybe vulnerable as well to the probiotics. In the experimental models, they showed that the *Enterococcus faecium* NCIMB-10415 results in the increase of the nitric oxide, which results in the increase in the IL-6 and IL-8 expressions. Rather than that, *Enterococcus faecium* HDRf-1 has the ability for modifying the levels of the pro-inflammatory cytokines (TNF-alpha, IL1, IL-6, IL8, IL-12, IL-17) (Morais et al., 2020; Walton et al., 2020).

Amongst the elderly and immunocompromised patients, the group of the gut probiotics is typically low, which is why those patients endure severe COVID-19 impacts (Viana et al., 2020). The Probiotic anti-inflammatory secretions have the ability of regulating this inflammatory reaction through the co-supplementation of the personalized functional food that incorporates probiotic types (Antunes et al., 2020).

As therapeutic solutions are lingering for the COVID-19, care has been focused upon the sufficient nutritional therapies. Some of the latest reviews have highlighted the probiotics as adjunct alternatives amongst the therapies that are available for treatments for overcoming new corona virus (Aarti et al., 2020; Akour, 2020; Lisa et al., 2020).

In addition, *Lactobacillus gasseri* has an impact on the management of the purine as adjuvant nutritional treatment for helping the treatment of COVID-19 in weakening the viral replications (Morais et al., 2020). Numerous experimental researches have proven that probiotic *Lactobacillus rhamnosus* GG play a role in the secretion of protein p 40, reducing the TNF, IL6, IFN-gamma, and chemo-attractant for the prevention of the inflammations in the epithelium of the gut (Yan et al., 2011).

A combination of *Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus casei* as well as secretions of other probiotics had stimulated the DC functions and downregulated Th 1, Th 2 and other factors, inducing the inflammation in lungs and gut via gut–lung axis link (Yang et al., 2020).

Plaza-Díaz et al. (2017) reported that the administrations of the probiotics has resulted in the reductions of systemic pro-inflammatory bio-markers in the non-gastrointestinal as well as the gastrointestinal conditions in the patients who have colitis after 6-8 weeks of therapy. The results of the RNA sequencing obtained by Feng et al. (2020) showed that the receptors of coronavirus, which include the angiotensin-converting enzyme 2 (ACE-2) for SARS-CoV and SARS-CoV2, have been highly expressed in the human enteroctyes. It is interesting to notice that some of the potential target cells, which have constant expressions in small intestines, are constant at the same time as being changed continuously in the tissues of the lung. Which is why, the enterocytes can play the role of conserved cell reservoir for the corona viruses, a fact which has to draw attentions of the healthcare researchers to such SARS-CoV-2 infection site.

*Lactobacilli* have the ability block the viral particles’ attachment to the human cells. Such distinctive characteristic had opened a platform for discovering the likelihood of the use of that microbe for the purpose of developing a local anti-viral nasal lactobacilli spray (Hanifi et al., 2020). Working on the nasal lactobacilli strains with the immune-stimulatory impacts for the purpose of using it as intra-nasal SARS-CoV2 vaccine adjuvants. Moreover, attempts for making the genetically engineered antigen-producing lactobacilli for the delivery of the vaccine are in progress.
The viruses account for over 90% of the infections of the upper respiratory tract and numerous reports have informed potential of the probiotics of the lactobacilli on preventing the infections of the upper respiratory tract. SARS-CoV2 spread through the respiratory droplets attempts at developing anti-viral probiotic nasal spray can have a protective impact (Suet et al., 2020).

3. Conclusion

Probiotics enhance the immune system and modulate the immune response. Immunomodulatory benefit in SARS-COV-2 reduce the inflammation (tissue injury in respiratory tract) and decrease the symptoms of gastrointestinal. Probiotics stimulation of IgA in mucosal layer of gastrointestinal tract/respiratory tract and control the infection and this promoted an attention in probiotics of new generation to support immunity towards the treatment of COVID-19 viruses. Also, develop anti-viral probiotic (lactobacilli) nasal spray may be protective patient against infection.

References


